Research

  • Disrupting the Differentiation of Cancer Stem Cells to Prevent the Spread of Hemangiosarcoma

    Hemangiosarcoma is a rapidly fatal disease. The lifetime risk is alarmingly high for some breeds like Golden Retrievers (~20% will die of this disease) and Portuguese Water Dogs (~15% will die of this disease). The risk of hemangiosarcoma is not limited to just these breeds but is considered a research

    Continue reading
  • Developing Ways to Improve Cancer Treatments

    Methods of predicting tumor response to a given chemotherapy protocol have historically focused on a few traits that could be measured in biopsy samples. Recent approaches have looked at the activity of genes within tumors to predict a tumor’s sensitivity to a given drug. Because many dogs with osteosarcoma eventually

    Continue reading
  • Assessing How a Protein Helps Hemangiosarcoma Cells Survive

    Canine hemangiosarcoma is a common and highly fatal cancer in dogs. Recent evidence suggests that populations of cancer stem cells give rise to tumors, promote tumor growth and are the main culprits behind drug resistance and disease recurrence. This study examines how a protein expressed by stem cells contributes to

    Continue reading
  • Determining a More Effective Treatment for Canine Lymphoma

    This study evaluates the efficacy of two antibodies that could treat canine B-cell lymphoma. The investigators theorize that either antibody alone will kill lymphoma cells and delay tumor progression but that the combined effect of the two antibodies will be more effective as a treatment for dogs with lymphoma. Co-sponsored

    Continue reading
  • Evaluating a Novel Drug for Lymphoma

    Lymphoma accounts for an estimated 25 percent of all canine cancers. This study investigates a new therapeutic antibody that appears to effectively kill canine lymphoma cells but does not appear to result in serious side effects. Researchers will work to find the best dosage and evaluate the drug’s safety and

    Continue reading
  • Searching for Ways to Control Hemangiosarcoma Cancer Cells in Dogs

    Hemangiosarcoma is a highly metastatic and incurable cancer that can affect dogs at any age. It is particularly prevalent in certain breeds such as Golden Retrievers, German Shepherds and Portuguese Water Dogs. Unfortunately, hemangiosarcoma is a disease that is poorly understood and for which there are currently no good treatment

    Continue reading
  • Plasma Cortisol Concentration in Dogs with Pituitary Dependent Hyperadrenocorticism and Atypical Cushing’s Syndrome

    To use a modified version of intermittent samplings to assess whether dogs with atypical Cushing’s syndrome produce increased cortisol over a certain time period. Results Twenty-eight dogs were enrolled in the study to compare cortisol concentrations among healthy dogs, dogs with excess cortisol associated with pituitary dependent Cushing’s syndrome and

    Continue reading
  • Genetic Background and the Angiogenic Phenotype in Cancer

    This project will continue the researchers’ observations on gene appearance profiles in hemangiosarcoma from Golden Retrievers to German Shepherd Dogs and Portuguese Water Dogs, and it also will define how new targeted therapies may effectively control the disease in these and other dog breeds. Results Certain dog breeds are prone

    Continue reading
  • Understanding the Role of Specific Cells in Spreading Lymphoma

    One of the limitations in identifying therapeutic targets for canine lymphoma has been the lack of reliable systems to study lymphoma cells in the laboratory. This study uses a culture system, developed by the principal investigator, to maintain lymphoma cells in the laboratory and study a protein that helps lymphoma

    Continue reading
  • Developing a New Treatment for Canine Lymphoma

    To develop a drug similar to Rituximab that works on canine lymphoma patients. Blood cell lymphomas affect about 30 dogs in every 100,000. Diffuse large B cell lymphoma (DLBCL) is a common type affecting dogs and is similar to non-Hodgkin’s lymphoma in humans. Current treatment induces remission in about 75

    Continue reading